I
4.25
-0.02 (-0.47%)
| Penutupan Terdahulu | 4.27 |
| Buka | 4.30 |
| Jumlah Dagangan | 598,027 |
| Purata Dagangan (3B) | 1,882,343 |
| Modal Pasaran | 533,681,856 |
| Harga / Jualan (P/S) | 25.39 |
| Harga / Buku (P/B) | 2.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -0.550 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.86% |
| Nisbah Semasa (MRQ) | 22.35 |
| Aliran Tunai Operasi (OCF TTM) | -52.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.15 M |
| Pulangan Atas Aset (ROA TTM) | -11.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | I-MAB | Bercampur | Menaik |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.00 |
|
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.80% |
| % Dimiliki oleh Institusi | 29.64% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |